COSMO Pharmaceuticals Financials
| COPN Stock | CHF 61.30 0.80 1.32% |
COSMO |
Understanding current and past COSMO Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of COSMO Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in COSMO Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in COSMO Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of COSMO Pharmaceuticals SA. Check COSMO Pharmaceuticals' Beneish M Score to see the likelihood of COSMO Pharmaceuticals' management manipulating its earnings.
COSMO Pharmaceuticals Stock Summary
COSMO Pharmaceuticals competes with Basilea Pharmaceutica, Newron Pharmaceuticals, Santhera Pharmaceuticals, and Evolva Holding. Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, develops, manufactures, and distributes products for gastroenterology and endoscopy worldwide. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland. COSMO PHARM operates under Drug Manufacturers - Major classification in Switzerland and is traded on Switzerland Exchange. It employs 306 people.| Instrument | Switzerland Stock View All |
| Exchange | SIX Swiss Exchange |
| ISIN | NL0011832936 |
| Business Address | Riverside II, Dublin, |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Major |
| Benchmark | Dow Jones Industrial |
| Website | www.cosmopharma.com |
| Phone | 353 1 817 0370 |
| Currency | CHF - Swiss Franc |
You should never invest in COSMO Pharmaceuticals without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of COSMO Stock, because this is throwing your money away. Analyzing the key information contained in COSMO Pharmaceuticals' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
COSMO Pharmaceuticals Key Financial Ratios
There are many critical financial ratios that COSMO Pharmaceuticals' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that COSMO Pharmaceuticals reports annually and quarterly.| Return On Equity | 0.0841 | |||
| Return On Asset | 0.0181 | |||
| Target Price | 86.03 | |||
| Number Of Employees | 292 | |||
| Beta | 1.07 |
COSMO Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining COSMO Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare COSMO Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across COSMO Pharmaceuticals competition to find correlations between indicators driving COSMO Pharmaceuticals's intrinsic value. More Info.COSMO Pharmaceuticals SA is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.22 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for COSMO Pharmaceuticals SA is roughly 4.65 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the COSMO Pharmaceuticals' earnings, one of the primary drivers of an investment's value.COSMO Pharmaceuticals Systematic Risk
COSMO Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. COSMO Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on COSMO Pharmaceuticals correlated with the market. If Beta is less than 0 COSMO Pharmaceuticals generally moves in the opposite direction as compared to the market. If COSMO Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one COSMO Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of COSMO Pharmaceuticals is generally in the same direction as the market. If Beta > 1 COSMO Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
COSMO Pharmaceuticals December 12, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of COSMO Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of COSMO Pharmaceuticals SA. We use our internally-developed statistical techniques to arrive at the intrinsic value of COSMO Pharmaceuticals SA based on widely used predictive technical indicators. In general, we focus on analyzing COSMO Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build COSMO Pharmaceuticals's daily price indicators and compare them against related drivers.
| Information Ratio | (0.54) | |||
| Maximum Drawdown | 4.19 | |||
| Value At Risk | (1.91) | |||
| Potential Upside | 1.45 |
Additional Tools for COSMO Stock Analysis
When running COSMO Pharmaceuticals' price analysis, check to measure COSMO Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy COSMO Pharmaceuticals is operating at the current time. Most of COSMO Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of COSMO Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move COSMO Pharmaceuticals' price. Additionally, you may evaluate how the addition of COSMO Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.